Literature DB >> 33842852

Broadening the spectrum of cancer genes under selection in human populations.

Konstantinos Voskarides1.   

Abstract

Entities:  

Year:  2021        PMID: 33842852      PMCID: PMC8019256          DOI: 10.1096/fba.2020-00150

Source DB:  PubMed          Journal:  FASEB Bioadv        ISSN: 2573-9832


× No keyword cloud information.
There is an increasing accumulation of evidence showing that the frequency of many human diseases has been formed by evolutionary procedures. Siddiqui et al. performed an amazing study published in this journal, showing that SIGLEC12 gene expression is associated with advanced cancer progression in humans. They performed a multi‐level experimental and statistical analysis. In a multi‐tissue carcinoma array, the gene product was present in ~80% of tissues and only 35% in a set of normal epithelial tissues. Forced expression of the gene in a SIGLEC12 null carcinoma cell line had the consequence of enriching the transcription of genes associated with cancer progression, especially those related with KRAS and YAP/TAZ pathways. Compared with chimpanzees, it seems that the human receptor Siglec12 has lost its ligand after the human/chimpanzee lineage split, but notably the ligand gene remained in the chimpanzee genome. The authors also found evidence, using the Fst and Tajima D statistics, that a SIGLEC12 null allele in human populations, ranging from 38% in sub‐Saharan Africans to 86% in native American populations, is under positive selection. They propose that the functional SIGLEC12 gene is currently under an elimination process in human populations, since its encoded protein, for unknown reasons, activates carcinogenic pathways. This study of Siddiqui et al. adds to previous studies that showed significant evidence for the action of natural selection on cancer genes. All human populations have high incidences of cancer, but some have especially much higher risk for certain cancer types. Voskarides has presented data showing that populations living in extreme cold environments and extreme high altitudes have the highest cancer incidence in the world. Linear regression analysis supports the fact that the cancer‐cold association is a world‐wide phenomenon. Analysis of 247 Genome Wide Association Studies (GWAS) showed that this association has a genetic base. Cancer genes and especially tumor suppressor genes were found to be under selection in Inuit, Eskimos and Alaska Indians. Genetic variants that contributed to the survival of humans in extreme environments are probably associated with cancer incidence today. A similar evolutionary process was revealed for human populations living at extreme high altitudes, like Ethiopians and Andeans (high cancer rates, tumor suppressor genes under selection). A supporting fact is that previous studies showed that p53 mutations causing cancer in humans were found to be significant for the survival of some mammal species in the Tibetan highlands. These results were published in 2004 and 2013 by two different research teams. They found that in three different rodent species living under extreme environmental conditions (cold, hypoxia), certain amino acids in two conserved p53 residue positions (R174, S106) render p53 unable to activate apoptosis pathways. , It seems that resistance to apoptosis, a carcinogenic trait, it's an advantage under certain environmental conditions. This is related to a special evolutionary process known as "antagonistic pleiotropy", first proposed by George Williams, one of the most well‐known evolutionary biologists of the past century. He suggested that genetic variants selected as beneficial for survival at young ages, may have a deleterious effect later in life. , Selection of deleterious variants in DNA repair genes (considered as one of the main classes of tumor suppressor genes in mammals) is vital for unicellular organisms escaping extinction. Bacteria, protozoa, and monocellular fungi become very resistant under stressful conditions (antibiotics, oxidative stress, nutrient limitation, and other) when carrying mutations in DNA repair genes like MSH2, PMS1, RAD51, and others. , , , When these genes malfunction, the mutation flow is increasing and so are the probabilities for a beneficial mutation to appear. Weak selection on certain traits (the trait here is mutagenesis rate) is called relaxed selection. When environmental conditions come back to normal, these mutations can be gradually decreased or eliminated from unicellular populations. Has this phenomenon remained conserved in multicellular organisms? Martincorena et al. has found thousands of deleterious mutations in cells of healthy esophageal tissue from healthy individuals, in 14 well‐known cancer genes. Further analysis showed that these genes are under strong positive selection. The two most mutated genes are NOTCH1 and TP53, genes that are frequently found mutated in esophageal cancer. Similar findings were published afterwards for other human tissues. , , Maybe we have to re‐consider our beliefs about deleteriousness of mutations in cancer genes. Our cells, especially those living under challenging conditions, probably accumulate deleterious mutations in cell cycle, apoptosis and DNA repair genes, in order to resist toxic agents and survive. There are also examples of genetic variants that appear to involve cancer risk and reproduction. Every biologist knows that mutations in the BRCA1/2 genes can cause ovarian and breast cancer. Utah women carrying pathogenic mutations in BRCA1/2 genes and living under natural fertility conditions (born before 1930) had more children, shorter interbirth intervals, later age at last birth, and higher post‐reproductive mortality than healthy controls. This pattern was absent in women living in environments with modern contraception. Scientists trying to confirm these data, found mixed results. , , Evidence of positive selection has been found only for the BRCA2 gene. Summarizing, I think that it is presently a fact that cancer is an 100% evolutionary phenomenon. Modern studies allow scientists to realize the action of natural selection on cancer genes, cancer cells, individuals, and populations. Unfortunately, it is very hard for natural selection to eliminate mutations that cause cancer after the end of the reproductive age. It is even harder when cancer mutations have a dual effect by increasing adaptation. Taking examples from unicellular organisms, it is possible that these deleterious mutations appear and disappear through a cycle procedure, that we poorly understand and is not yet proven in multicellular organisms. If it occurs, this cycle is spread over hundreds of thousands of years, thus it is difficult to study and confirm. Extreme events like famine, pandemics, radical climate change etc. can disrupt this cycle and mutation‐selection equilibria may take too long to be stabilized. Maybe we have to find suitable animal models to simulate evolution in the laboratory to understand further these procedures.
  21 in total

1.  Antagonistic pleiotropy and mutation accumulation influence human senescence and disease.

Authors:  Juan Antonio Rodríguez; Urko M Marigorta; David A Hughes; Nino Spataro; Elena Bosch; Arcadi Navarro
Journal:  Nat Ecol Evol       Date:  2017-01-30       Impact factor: 15.460

2.  Effects of BRCA1 and BRCA2 mutations on female fertility.

Authors:  Ken R Smith; Heidi A Hanson; Geraldine P Mineau; Saundra S Buys
Journal:  Proc Biol Sci       Date:  2011-10-12       Impact factor: 5.349

3.  Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan.

Authors:  Jesse J Salk; Kaitlyn Loubet-Senear; Elisabeth Maritschnegg; Charles C Valentine; Lindsey N Williams; Jacob E Higgins; Reinhard Horvat; Adriaan Vanderstichele; Daniela Nachmanson; Kathryn T Baker; Mary J Emond; Emily Loter; Maria Tretiakova; Thierry Soussi; Lawrence A Loeb; Robert Zeillinger; Paul Speiser; Rosa Ana Risques
Journal:  Cell Rep       Date:  2019-07-02       Impact factor: 9.423

4.  Codon 104 variation of p53 gene provides adaptive apoptotic responses to extreme environments in mammals of the Tibet plateau.

Authors:  Yang Zhao; Ji-Long Ren; Ming-Yang Wang; Sheng-Ting Zhang; Yu Liu; Min Li; Yi-Bin Cao; Hu-Yue Zu; Xiao-Cheng Chen; Chung-I Wu; Eviatar Nevo; Xue-Qun Chen; Ji-Zeng Du
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

5.  Fertility in women with BRCA mutations: a case-control study.

Authors:  Tuya Pal; David Keefe; Ping Sun; Steven A Narod
Journal:  Fertil Steril       Date:  2009-02-06       Impact factor: 7.329

6.  Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation.

Authors:  Osnat Ashur-Fabian; Aaron Avivi; Luba Trakhtenbrot; Konstantin Adamsky; Meytal Cohen; Gadi Kajakaro; Alma Joel; Ninette Amariglio; Eviatar Nevo; Gideon Rechavi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-09       Impact factor: 11.205

Review 7.  Is antagonistic pleiotropy ubiquitous in aging biology?

Authors:  Steven N Austad; Jessica M Hoffman
Journal:  Evol Med Public Health       Date:  2018-10-11

8.  Genes that improved fitness also cost modern humans: evidence for genes with antagonistic effects on longevity and disease.

Authors:  Sean G Byars; Konstantinos Voskarides
Journal:  Evol Med Public Health       Date:  2019-01-23

9.  Evolution of extreme resistance to ionizing radiation via genetic adaptation of DNA repair.

Authors:  Rose T Byrne; Audrey J Klingele; Eric L Cabot; Wendy S Schackwitz; Jeffrey A Martin; Joel Martin; Zhong Wang; Elizabeth A Wood; Christa Pennacchio; Len A Pennacchio; Nicole T Perna; John R Battista; Michael M Cox
Journal:  Elife       Date:  2014-03-04       Impact factor: 8.140

10.  Population dynamics of normal human blood inferred from somatic mutations.

Authors:  Henry Lee-Six; Nina Friesgaard Øbro; Mairi S Shepherd; Sebastian Grossmann; Kevin Dawson; Miriam Belmonte; Robert J Osborne; Brian J P Huntly; Inigo Martincorena; Elizabeth Anderson; Laura O'Neill; Michael R Stratton; Elisa Laurenti; Anthony R Green; David G Kent; Peter J Campbell
Journal:  Nature       Date:  2018-09-05       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.